Amrit Ray
Known title: DirectorCIK: 0001924797
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.
Transaction History
| FTRE | ▲ Buy | Option Exercise | 38,817 | $0 | 6/10/2026 | View on chart |
| RARE | ▲ Buy | Grant | 7,751 | $0 | 5/14/2026 | View on chart |
| RARE | ▲ Buy | Grant | 5,740 | $0 | 5/15/2025 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 7,282 | $0 | 5/14/2025 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 6,354 | $0 | 7/18/2024 | View on chart |
| RARE | ▲ Buy | Grant | 5,345 | $0 | 6/18/2024 | View on chart |
| RARE | ▲ Buy | Grant | 3,860 | $0 | 6/7/2023 | View on chart |
| RARE | ▲ Buy | Grant | 3,300 | $0 | 6/24/2022 | View on chart |
| RARE | ▲ Buy | Grant | 5,120 | $0 | 4/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Barclays Upgrades Fortrea, Boosts Target to $23
Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.
Barclays Upgrades Fortrea, Boosts Target to $23. Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.